Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O pro­grams

Lara Sul­li­van knows how em­pow­er­ing it can be for a biotech to bring in ex­per­i­men­tal drugs from Pfiz­er’s shelves. An alum of the phar­ma gi­ant’s ear­ly stage R&D port­fo­lio op­er­a­tions and strat­e­gy team, she helped spin out four or­phan dis­ease meds in­to Spring­Works Ther­a­peu­tics, which earned some sig­nif­i­cant back­ing from Bain be­fore vault­ing to a $186 mil­lion IPO with­in two years.

So when some of her old col­leagues got in touch about an an­ti­body-drug con­ju­gate pro­gram that they were shut­ter­ing — just as she was set­tling in­to her new role as CEO of Pyx­is On­col­o­gy — Sul­li­van jumped at the op­por­tu­ni­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER